Novo Nordisk to Double China R&D Headcount

Novo Nordisk will expand its Beijing R&D center from 100 employees currently to 200 by 2015. The expansion will create a new Diabetes Research Unit, capable of performing all stages of drug development. At the same time, the company said it expects its China sales to grow at the same 20% annual rate as China healthcare spending, which will take its revenues in China to $1.75 billion by 2015. More details.... Stock Symbol: (NYSE: NVO)